News Headlines Article

80% of oncologists prefer medications with no patient out-of-pocket costs
Sacramento Bee

PediatRx, Inc. (OTCBB: PEDX), a hospital specialty company with a focus on oncology supportive care, recently polled a representative sample of approximately 70 US oncologists and other physician specialists and found that the majority (78%) viewed “no patient out-of-pocket costs” as a motivating factor for prescribing GRANISOL. GRANISOL is the only FDA-approved oral solution of granisetron, a medication used to prevent nausea and vomiting in patients undergoing chemotherapy or radiotherapy for cancer.